CIA
RPRX icon

Cape Investment Advisory’s Royalty Pharma RPRX Stock Holding History

Cape Investment Advisory’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6K Buy
+107
New +$5.57K ﹤0.01% 984
2026
Q1 		– Sell
-107
Closed -$4.13K – 980
2025
Q4 		$4.13K Buy
+107
New +$4.08K ﹤0.01% 951
2025
Q3 		– Sell
-36
Closed -$1.3K – 1121
2025
Q2 		$1.3K Hold
36
– – ﹤0.01% 1004
2025
Q1 		$1.12K Hold
36
– – ﹤0.01% 955
2024
Q4 		$918 Buy
+36
New +$955 ﹤0.01% 973

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cape Investment Advisory's RPRX Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Royalty Pharma (RPRX) in Q2 2026: 107 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #984 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in RPRX as recently as Q4 2025.

Cape Investment Advisory first reported a position in RPRX in Q4 2024 and has held it in 5 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Cape Investment Advisory held 107 shares of Royalty Pharma worth $6K as of Q2 2026.
  • Royalty Pharma was a new Cape Investment Advisory position in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #984 holding.
  • Cape Investment Advisory first reported a position in Royalty Pharma in Q4 2024 and has held it in 5 quarters since.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.